scispace - formally typeset
P

Pravin T. P. Kaumaya

Researcher at Ohio State University

Publications -  83
Citations -  1990

Pravin T. P. Kaumaya is an academic researcher from Ohio State University. The author has contributed to research in topics: Epitope & Peptide vaccine. The author has an hindex of 28, co-authored 79 publications receiving 1803 citations. Previous affiliations of Pravin T. P. Kaumaya include National Institutes of Health & University of Minnesota.

Papers
More filters
Journal ArticleDOI

The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway.

TL;DR: This is the first report demonstrating that a nonstructural protein encoded by EBV is a pathogen-associated molecular pattern and that it has immunomodulatory functions and the dUTPase could be a potential target for the development of novel therapeutic agents against infections caused byEBV.
Journal ArticleDOI

Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable Haemophilus influenzae in the chinchilla

TL;DR: Two peptides which incorporate determinants of the fimbrial subunit co-linearly synthesized with a "promiscuous" T-cell epitope from the fusion protein of measles virus are synthesized.
Journal ArticleDOI

A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses

TL;DR: This multiepitope vaccine in combination with IL-12 caused a significant reduction in the number of pulmonary metastases induced by challenge with syngeneic tumor cells overexpressing HER-2, and may have potential application in the treatment of Her-2-associated cancers.
Journal ArticleDOI

Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.

TL;DR: Egged tow peptides to encompass the sequences from the universally immunogenic tetanus toxoid (TT) epitope and the contraceptive vaccine candidate lactate dehydrogenase C4 are engineered, demonstrating the feasibility of using ‘promiscuous’ T‐Cell epitopes colinearly constructed with a defined B‐cell epitope to induce high titer antipeptide IgG antibodies specific for native protein antigen LDH‐C4 in several inbred strains of mice, outbred
Journal ArticleDOI

Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.

TL;DR: The data demonstrate that the antibody response to retroviral peptides is enhanced by promiscuous peptide constructs, in part because of the ability of such constructs to promote appropriate secondary structural forms of viral epitopes.